Trial · NCT00823199
An Open Trial of Allopurinol in Patients With Poorly Responsive Schizophrenia
NCT00823199, Not applicable, Completed, Bronx Psychiatric Center; results first posted 2013-05-03
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. An Open Trial of Allopurinol in Patients With Poorly Responsive Schizophrenia. Trials, record NCT00823199. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00823199
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- An Open Trial of Allopurinol in Patients With Poorly Responsive Schizophrenia
- NCT number
- NCT00823199
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 10 participants, actual
- Lead sponsor
- Bronx Psychiatric Center
- Conditions
- Schizophrenia
- Interventions
- Allopurinal
- First posted
- 2009-01-15
- Last updated
- 2018-08-21
- Results first posted
- 2013-05-03
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Positive and Negative Syndrome Scale (PANSS) Measures Symptoms of Schizophrenia | baseline and 4 weeks | Symptom scale Score 30 (best, no symptoms of schizophrenia) to 210 (worst) |
| Secondary | Simpson Angus Scale for Parkinsonism | baseline and 4 weeks | Measures drug induced parkinsonism, score 0 (best, no Parkinsonism) to 36 (worst) |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Positive and Negative Syndrome Scale (PANSS) Measures Symptoms of Schizophrenia | baseline and 4 weeks | Two subjects withdrew before the first week's evaluation | scores on a scale | MEAN |
| SECONDARY | Simpson Angus Scale for Parkinsonism | baseline and 4 weeks | score on scale | MEAN | |
| POST_HOC | Uric Acid Level | Baseline and 4 weeks | 2 subjects had missing data | mg/dL | MEAN |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Positive and Negative Syndrome Scale (PANSS) Measures Symptoms of Schizophrenia | Allopurinal Treatment | Baseline | 95 | Standard Deviation 22 | scores on a scale |
| Change in Positive and Negative Syndrome Scale (PANSS) Measures Symptoms of Schizophrenia | Allopurinal Treatment | End | 75 | Standard Deviation 17 | scores on a scale |
| Simpson Angus Scale for Parkinsonism | Allopurinal Treatment | Baseline | 0.37 | Standard Deviation 0.74 | score on scale |
| Simpson Angus Scale for Parkinsonism | Allopurinal Treatment | End | 1.75 | Standard Deviation 3.1 | score on scale |
| Uric Acid Level | Allopurinal Treatment | Baseline | 5.9 | Standard Deviation 1.7 | mg/dL |
| Uric Acid Level | Allopurinal Treatment | End | 3.8 | Standard Deviation 0.7 | mg/dL |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Allopurinal Treatment | 10 | |
| Overall Study | COMPLETED | Allopurinal Treatment | 8 | |
| Overall Study | NOT COMPLETED | Allopurinal Treatment | 2 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Group 1 | ||
| Total, other adverse events | Group 1 | 0 | 10 |
| Total, serious adverse events | Group 1 | 0 | 10 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00823199
GET https://conductscience.org/api/trials/v1/NCT00823199/registered